Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA-CD19 cCAR T Cells for Relapsed/Refractory SLE
NCT05474885Phase 1Unknown
- Sponsor
- iCell Gene Therapeutics
- Start
- Apr 2022
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BCMA-CD19 cCAR-T in systemic lupus erythematosus (SLE), sponsored by iCell Gene Therapeutics. Primary endpoint: Number and incidence of adverse events at 3 months. Status: unknown.
02
Drugs
BCMA-CD19 cCAR-T
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT05474885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05474885.